Opportunity Information: Apply for PAR 07 214
Apply for PAR 07 214
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Academic Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Feb 12, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Private institutions of higher education.
- Foreign institutions are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), offered this grant opportunity to push promising in vivo imaging and spectroscopy technologies out of the lab and into real cancer research and clinical use. The program uses the NIH Research Project Grant (R01) mechanism and is built specifically around partnerships between academic researchers and industry investigators. The central idea is that imaging systems and methods often stall between prototype development and practical deployment, so the FOA focuses on accelerating that translation by combining academic innovation with industrial engineering, product development, and deployment experience.
At the core of the announcement is the requirement for an interdisciplinary, multi-institutional team formed jointly by academic and industrial partners. Applicants are expected to work together to develop, improve, and validate in vivo spectroscopic and imaging technologies so they can be applied credibly in human studies, animal studies, cancer research projects, clinical trials, and potentially routine clinical practice. In practical terms, this means the partnership should not be a loose collaboration; it should be organized to move an imaging approach along the pipeline from technical advancement through testing and validation in living systems, with attention to the performance, reliability, and usability needed for real biomedical and clinical environments.
The opportunity falls under NIH and NCI cancer research areas tied to cancer detection and diagnosis, cancer treatment, and cancer biology (CFDA 93.394, 93.395, and 93.396). While the title highlights imaging systems and methods, the intent is broader than building hardware alone. The scope includes development and validation of in vivo imaging and spectroscopic approaches that can meaningfully support cancer investigations, such as improving how tumors are detected, characterized, monitored over time, or assessed for response to therapy. The FOA is explicitly oriented toward translation, so projects are expected to advance imaging technology toward application in animal or human studies rather than stopping at proof-of-concept demonstrations.
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (other than small businesses), small businesses, and additional categories referenced in the full announcement. Foreign institutions are also eligible to apply, which indicates the program was open to international participation as long as the proposed partnership and project met NIH requirements. There is no cost sharing or matching requirement, meaning applicants were not required to provide non-federal matching funds as a condition of the award.
Administratively, this is a discretionary grant program with multiple receipt dates rather than a single deadline, and applicants were directed to the full FOA for the specific schedule and submission details. The funding opportunity number is PAR-07-214, and it was originally posted on February 12, 2007, with an archive date of April 5, 2010. The official posting includes a link to the full announcement on the NIH grants website, and NIH provided webmaster contacts for access or technical linking issues.
Frequently Asked Questions (FAQs)
What is this grant opportunity?
This opportunity is a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement intended to move promising in vivo imaging and spectroscopy technologies from laboratory prototypes into practical cancer research and clinical use. It targets the gap where imaging systems and methods often stall between initial development and real-world deployment.
What NIH grant mechanism does this program use?
The program uses the NIH Research Project Grant (R01) mechanism.
What is the main goal of the funding opportunity?
The main goal is to accelerate translation of in vivo imaging and spectroscopic technologies by combining academic innovation with industry capabilities in engineering, product development, and deployment. The emphasis is on advancing technologies beyond proof-of-concept so they can be credibly applied in animal studies, human studies, cancer research projects, clinical trials, and potentially routine clinical practice.
Why does the FOA require academic and industry partnerships?
The FOA is built around the idea that translation often stalls without both academic discovery and industrial development expertise. Academic researchers contribute innovation and scientific development, while industry investigators contribute engineering rigor, product development, and experience deploying tools in real biomedical and clinical environments.
Is an academic-industry partnership required, or just encouraged?
Based on the announcement summary, the program is built specifically around partnerships between academic researchers and industry investigators, and it requires an interdisciplinary, multi-institutional team formed jointly by academic and industrial partners.
What kind of team structure is expected?
An interdisciplinary, multi-institutional team jointly formed by academic and industry partners. The partnership is expected to be organized to move an imaging approach along the pipeline from technical advancement through testing and validation in living systems, with attention to performance, reliability, and usability for biomedical and clinical environments.
Does the program focus only on building imaging hardware?
No. While imaging systems and methods are highlighted, the intent is broader than hardware alone. The scope includes development and validation of in vivo imaging and spectroscopic approaches that can meaningfully support cancer investigations.
What types of research or use cases are within scope?
Projects may focus on imaging and spectroscopy approaches that improve how tumors are detected, characterized, monitored over time, or assessed for response to therapy. The projects are expected to support credible application in cancer research contexts such as animal studies, human studies, cancer research projects, and clinical trials, with potential to move toward routine clinical practice.
What does "translation" mean in the context of this FOA?
In this FOA, translation means moving technologies from prototype development toward practical deployment in real studies. Projects are expected to advance technology toward application in animal or human studies rather than stopping at proof-of-concept demonstrations.
What areas of cancer research does this opportunity relate to?
The opportunity falls under NIH and NCI cancer research areas tied to cancer detection and diagnosis, cancer treatment, and cancer biology.
Which CFDA program areas are referenced?
The announcement references CFDA numbers 93.394, 93.395, and 93.396.
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), for-profit organizations (other than small businesses), small businesses, and additional categories referenced in the full announcement.
Are foreign institutions eligible?
Yes. Foreign institutions are eligible to apply, indicating the program was open to international participation as long as the proposed partnership and project met NIH requirements.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement, meaning applicants were not required to provide non-federal matching funds as a condition of the award.
What type of funding program is this administratively?
It is described as a discretionary grant program.
Is there a single deadline to apply?
No. The announcement notes multiple receipt dates rather than a single deadline, and applicants were directed to the full FOA for the specific schedule and submission details.
What is the funding opportunity number?
The funding opportunity number is PAR-07-214.
When was the opportunity posted and when was it archived?
It was originally posted on February 12, 2007, and it has an archive date of April 5, 2010.
Where can applicants find the official full announcement?
The official posting includes a link to the full announcement on the NIH grants website.
Who should be contacted for technical issues with accessing or linking to the announcement?
NIH provided webmaster contacts for access or technical linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Alcohol Use Disorders Treatment, Services Research, and Recovery (R03)
Previous opportunity: Global Research Initiative Program, Behavioral/Social Sciences (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 07 214
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 07 214) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDA Research Education Grants in Drug Abuse and Addiction (R25) Apply for PAR 07 221 Funding Number: PAR 07 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R01) Apply for PA 07 226 Funding Number: PA 07 226 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R21) Apply for PA 07 227 Funding Number: PA 07 227 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Neuroscience Research on Drug Abuse(R03) Apply for PA 07 228 Funding Number: PA 07 228 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Collaborative Clinical Trials in Drug Abuse (R01) Apply for PAR 07 232 Funding Number: PAR 07 232 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01) Apply for PA 07 329 Funding Number: PA 07 329 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21) Apply for PA 07 331 Funding Number: PA 07 331 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03) Apply for PA 07 330 Funding Number: PA 07 330 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R01) Apply for PA 07 333 Funding Number: PA 07 333 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Amphetamine and Amphetamine Like Related Disorders (R21) Apply for PA 07 334 Funding Number: PA 07 334 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Animal Models and Related Biological Materials For Research (R21) Apply for PA 07 336 Funding Number: PA 07 336 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Treatment Adherence Research (R01) Apply for PA 07 338 Funding Number: PA 07 338 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Treatment Adherence Research (R03) Apply for PA 07 339 Funding Number: PA 07 339 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Treatment Adherence Research (R21) Apply for PA 07 340 Funding Number: PA 07 340 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Developing And Improving Institutional Animal Resources (G20) Apply for PAR 07 342 Funding Number: PAR 07 342 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| AIDS Science Track Award for Research Transition (R03) Apply for PA 07 349 Funding Number: PA 07 349 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Bioengineering and Obesity (R01) Apply for PA 07 354 Funding Number: PA 07 354 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Improving Heart Failure Disease Management (R01) Apply for PA 07 355 Funding Number: PA 07 355 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Clinical Cancer Therapy and Prevention Research (R01) Apply for PA 07 356 Funding Number: PA 07 356 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Cancer Prevention Studies Involving Molecular Targets for Bioactive Food Components (R21) Apply for PA 07 362 Funding Number: PA 07 362 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 07 214", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.